Science · Evolutionary Biology

Comparative Oncology: How Evolution Solved Cancer

Different species evolved different defenses against cancer. Some of them are better than ours. Nightbox borrows from the best.

The field

Comparative oncology is the study of cancer across species. The premise is straightforward: cancer isn't unique to humans. It shows up across virtually all multicellular life — mammals, birds, reptiles, fish, even insects and plants in their own way. But different species get cancer at wildly different rates, and the reasons are interesting.

For most of the 20th century, cancer research was almost exclusively conducted in humans and laboratory mice. Comparative approaches were considered too exotic to be practical. That started changing around 2010-2015, when genomic sequencing became cheap enough to study the cancer biology of non-model organisms systematically.

The standout species

Elephants

The elephant story is the one most relevant to our program. Elephants have ~100x more cells than humans and live 60-70 years, yet their lifetime cancer incidence is around 4.8% compared to our 17-25%. The primary mechanisms are TP53 retrogene expansion (20 copies vs. our 2) and the LIF6 pseudogene resurrection. The Nightbox chimera directly borrows the LIF6 mechanism. See our Peto's paradox page for the full story.

Naked mole rats

Naked mole rats are arguably the most cancer-resistant mammal known. In captive colonies of thousands of animals observed over decades, spontaneous tumors are vanishingly rare. Their mechanism is different from elephants — instead of enhanced apoptosis, naked mole rats use a hyaluronan-based contact inhibition system. They produce a very high molecular weight form of hyaluronic acid that triggers early contact inhibition, preventing cells from overcrowding even before they become cancerous. Tian et al. described this in a 2013 Nature paper.

This mechanism is harder to borrow for therapy because it relies on extracellular matrix composition rather than an intracellular effector, but it's a proof of concept that evolution can solve cancer through radically different approaches.

Bowhead whales

Bowhead whales live over 200 years and weigh up to 100 tons. By naive probability they should be solid tumors by age 50. They're not. Their genome shows duplications and unique mutations in DNA repair genes, cell cycle regulators, and the ERCC1/ERCC3 pathway. Keane et al. (2015, Cell Reports) sequenced the bowhead genome and identified these cancer-resistance adaptations.

Blind mole rats (Spalax)

Blind mole rats (not the same as naked mole rats) have yet another mechanism: they use a necrotic cell death pathway mediated by interferon-beta. When cells start proliferating abnormally, neighboring cells release IFN-beta which triggers concerted necrosis — killing the abnormal cells along with some innocent bystanders. It's messier than apoptosis but effective. Gorbunova et al. documented this in 2012.

What this means for therapy design

The overarching lesson from comparative oncology is that cancer is solvable. Evolution has solved it independently, through different mechanisms, in multiple lineages. The question for therapeutic design is: which of these solutions can be engineered into a human-compatible format?

We picked the elephant solution — LIF6-based mitochondrial apoptosis — because it's a single-gene effector with a clean mechanism, it can be gated by a human recognition module (NKG2D), and it fits within the AAV packaging limit. It's not the only comparative oncology approach that could work, but it's the one we can build and test with the tools available in 2026.

Other approaches — the naked mole rat's hyaluronan system, the whale's enhanced DNA repair, the blind mole rat's interferon-necrosis pathway — might inspire future programs. The field is wide open. Most pharma hasn't looked at it seriously.

The Nightbox cross-species analysis

Our in silico work modeled cancer progression across 8 species: naked mole rat, mouse, cat, dog, pig, elephant, blue whale, and human. The finding was that despite different mechanisms, cancer follows a conserved four-phase program across all 8 species: GROW (proliferation reactivation), EVADE (immune suppression), SLEEP (dormancy under therapeutic pressure), RESURRECT (apoptotic-debris-driven regrowth via PGE2). Breaking any phase disrupts the program.

NKG2D-LIF6 targets the GROW and RESURRECT phases simultaneously — NKG2D detects the growing tumor, LIF6 kills it by apoptosis, and because LIF6-driven apoptosis is p53-independent and doesn't generate the inflammatory debris that drives Phoenix Rising regrowth, it avoids the RESURRECT phase trap that makes conventional chemotherapy less effective.

All of that is computational. Real animals will tell us if it holds up.

Written by Artem Shakin, founder of Nightbox LLC. Published 2026-04-30. CC BY 4.0.